SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001829126-24-002110
Filing Date
2024-04-01
Accepted
2024-04-01 17:10:03
Documents
74
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K titanpharma_10k.htm   iXBRL 10-K 1295260
2 EXHIBIT 23.1 titanpharma_ex23-1.htm EX-23.1 2944
3 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 9127
4 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 4469
5 EXHIBIT 97.1 titanpharma_ex97i.htm EX-97.1 21080
  Complete submission text file 0001829126-24-002110.txt   6493942

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ttnp-20231231.xsd EX-101.SCH 46484
7 XBRL CALCULATION FILE ttnp-20231231_cal.xml EX-101.CAL 53842
8 XBRL DEFINITION FILE ttnp-20231231_def.xml EX-101.DEF 196563
9 XBRL LABEL FILE ttnp-20231231_lab.xml EX-101.LAB 388822
10 XBRL PRESENTATION FILE ttnp-20231231_pre.xml EX-101.PRE 351944
77 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10k_htm.xml XML 934410
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-13341 | Film No.: 24810789
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)